Possible mechanisms by which the gastrointestinal microbiome regulates anti-PD-1 immunotherapy include affecting the composition and function of immune cells, altering the expression of PD-L1 on tumor cells, and producing metabolites that regulate inflammation and immunity (Gopalakrishnan et al., 2018a; Miller and Carson, 2020). This evidence concerns the gene PDCD1 and neoplasm.